Three hundred and twenty-two (322) clinical isolates were collected from patients admitted to intensive care units (ICUs) at eight Swedish hospitals between December 1996 and December 1998. Of the isolates, 244 (76%) were Enterococcus faecalis, 74 (23%) were Enterococcus faecium and four (1%) were other Enterococcus spp. MICs of ampicillin, imipenem, meropenem, piperacillin/tazobactam, ciprofloxacin, trovafloxacin, clinafloxacin, gentamicin, streptomycin, vancomycin, teicoplanin, quinupristin/dalfopristin, linezolid and evernimicin were determined by Etest. Susceptible and resistant isolates were defined according to the species-related MIC breakpoints of the British Society for Antimicrobial Chemotherapy (BSAC), the National Committee for Clinical Laboratory Standards (NCCLS) and the Swedish Reference Group for Antibiotics (SRGA). Tentative breakpoints were applied for new/experimental antibiotics. Multidrug resistance among enterococci in ICUs is not uncommon in Sweden, particularly among E. faecium, and includes ampicillin resistance and concomitant resistance to fluoroquinolones. Almost 20% of E. faecalis isolates showed high-level resistance to gentamicin and concomitant resistance to fluoroquinolones. Vancomycin-resistant enterococci were only found sporadically. Among the new antimicrobial agents, linezolid and evernimicin showed the best activity against all enterococcal isolates. There was good concordance between the BSAC, NCCLS and SRGA breakpoints in detecting resistance. When applying the SRGA breakpoints for susceptibility, isolates were more frequently interpreted as intermediate. This might indicate earlier detection of emerging resistance using the SRGA breakpoint when the native population is considered susceptible, but with the risk that isolates belonging to the native susceptible population will be incorrectly interpreted as intermediate.
Introduction
Nosocomial infections caused by Gram-positive bacteria, including enterococci, are an increasing problem. Owing to invasive procedures, high antibiotic consumption and a patient population with serious underlying diseases, nosocomial infections are more frequent in intensive care units (ICUs) 1 compared with general hospital wards 2 and outbreaks often originate in ICUs. 3 Enterococci have been regarded as pathogens that seldom cause serious infections. 4 However, in the last decade they have emerged as an important cause of nosocomial infections, with an increasing frequency of multidrug resistance, including high-level resistance to gentamicin and resistance to ampicillin. [5] [6] [7] [8] Glycopeptide resistance among enterococci has become increasingly common in many European countries and in North America. [9] [10] [11] However, in Swedish hospitals only sporadic findings of glycopeptide-resistant enterococci have been reported. 12, 13 In order to achieve early detection of emerging resistance, species-related breakpoints have been introduced in recent years with the aim of setting the breakpoint for susceptibility as close as possible to the upper border of the MIC distribution of the native population of a specific species. [14] [15] [16] [17] The aim of this study was to investigate the MIC distribution of 14 17 and the Swedish Reference Group for Antibiotics (SRGA). 15 The purpose was also to determine the MIC distribution of some new antibiotics, i.e. trovafloxacin, clinafloxacin, quinupristin/dalfopristin, linezolid and evernimicin.
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Materials and methods
Study design and setting
A Swedish multicentre susceptibility study was performed on enterococcal isolates collected between December 1996 and December 1998 from patients admitted to ICUs at eight Swedish hospitals. Four hospitals were tertiary care (university) hospitals and four were secondary care (county) hospitals.
Bacterial cultures
Specimens collected on the basis of clinical indication, were cultured at each hospital (Table I) . When enterococci had been identified, they were sent to the Division of Clinical Microbiology at the Faculty of Health Science in Linköping for further analysis. All initial isolates were included. Repeat isolates of the same species from the same patient were only included if there was a difference in MICs of у2 dilution steps in at least one antibiotic compared with the initial isolate.
Identification of the isolates
Identification of enterococci to the species level was based on a series of conventional biochemical tests. 24, 25 Enterococcus faecalis ATCC 29212 and Enterococcus faecium ATCC 35667 were used as control strains. When biochemical tests were inconclusive and/or the MIC of vancomycin was Ͼ4 mg/L, detection of vancomycin resistance genes (vanA, vanB, vanC1 or vanC2/C3) with multiplex PCR was used as described by Monstein and co-workers. 26 The specimens were grown on paper disc method (PDM) agar plates (AB Biodisk, Solna, Sweden) with 5% defibrinated horse blood and with a vancomycin disc (AB Biodisk).
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Bacterial colonies close to the vancomycin disc were chosen for DNA extraction to make sure that they had not lost their resistance genes. The PCR amplifications were performed in a programmable thermal controller (GeneAmp PCR system 9600; Perkin Elmer, Beaconsfield, UK). The PCR products were analysed by 1.2% (w/v) agarose gel electrophoresis (E-Gel; Invitrogen, Groningen, The Netherlands) and stained with ethidium bromide. The gel was photographed in UV light and compared visually with positive controls for vanA (E. faecium HJ 8 27 ), vanB (E. faecalis HJ 2 27 ), vanC1 (Enterococcus gallinarium CCUG 18658) and vanC2/C3 (Enterococcus casseliflavus CCUG 18657/ATCC 25788). 
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Susceptibility testing
MICs of ampicillin, imipenem, meropenem, piperacillin/ tazobactam, ciprofloxacin, trovafloxacin, clinafloxacin, gentamicin, streptomycin, vancomycin, teicoplanin, quinupristin/dalfopristin, linezolid and evernimicin were determined by Etest (AB Biodisk), using a suspension equivalent to a 0.5 McFarland standard and PDM agar.
Plates were examined after 24 h incubation at 37°C for all antibiotics except gentamicin and streptomycin, which were examined after 48 h. 28 All isolates were tested for -lactamase production with the chromogenic nitrocefin disc test (AB Biodisk).
Breakpoints
Resistant and susceptible strains were defined according to the species-related MIC breakpoints of the BSAC, 16 the NCCLS 17 and the SRGA 15 (Table II) . For antibiotics where BSAC, NCCLS or SRGA breakpoints were not available, breakpoints suggested in earlier studies or pharmaceutical company breakpoint recommendations were applied (Table III) .
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Statistics
With respect to resistance to ampicillin or high-level resistance to gentamicin or streptomycin, isolates with or without concomitant resistance to fluoroquinolones were analysed using the 2 test. Results were considered significant when P Ͻ 0.01.
Results
Of the 322 enterococcal isolates, 244 were E. faecalis, 74 were E. faecium and four were other Enterococcus spp. Of these, three carried the vanC1 gene, and one the vanC2 gene. The sources of the isolates were mainly urine, respiratory tract and gastrointestinal tract (Table I) .
Percentages of susceptible and resistant isolates according to BSAC, NCCLS and SRGA, or tentative breakpoints, are shown in Tables III and IV, respectively. The MIC distributions of the antibiotics are shown in Table V .
Susceptibility to -lactam antibiotics
No -lactamase production was detected. Fifty-five isolates of E. faecium (74%) were resistant to ampicillin, but all isolates of E. faecalis were susceptible (Tables IV and V) . When applying the SRGA and the BSAC breakpoints for susceptibility to the MIC distribution of imipenem, 37% and 97%, respectively, of the E. faecalis isolates were interpreted as susceptible (Tables IV and V) . Similar results were seen with meropenem, where 9% were interpreted as susceptible using the SRGA breakpoints and 69% with the BSAC breakpoints (Tables IV and V) .
Susceptibility to quinolones
None of the enterococci were susceptible to ciprofloxacin using the SRGA breakpoint. Applying the NCCLS breakpoints, 12% of E. faecium isolates and 23% of E. faecalis isolates were susceptible (Tables IV and V) . Compared with ciprofloxacin, a higher number of isolates, 77% of E. faecalis and 20% of E. faecium, were susceptible to clinafloxacin (Tables III-V) . Nevertheless, a large number of isolates with resistance to the new quinolones, clinafloxacin and trovafloxacin, were found among E. faecalis (23%, both antibiotics) and E. faecium (62% and 68%, respectively). All but two isolates resistant to the new 55 quinolones were also resistant to ciprofloxacin (Tables  III-V) .
Of the 55 ampicillin-resistant isolates, 44 (80%) were resistant to all fluoroquinolones tested. In comparison, only one (5%) of the 19 ampicillin-susceptible E. faecium isolates was resistant to all of the fluoroquinolones ( 2 ϭ 33.10, P Ͻ 0.0001).
High-level resistance to aminoglycosides
Of the E. faecium isolates, 54% showed high-level streptomycin resistance (HLSR), but no high-level gentamicin resistance (HLGR) was found (Tables III-V) . Twenty per cent of the E. faecalis isolates showed HLGR, and 22% showed HLSR. All but one (98%) of the 48 E. faecalis 56 (Tables IV and V) .
Susceptibility to the new antibiotics
All strains of E. faecalis were resistant to quinupristin/ dalfopristin, except three isolates (1%) that were susceptible using the BSAC breakpoint and intermediate using the NCCLS breakpoints. For E. faecium, 78% and 98% were susceptible according to the NCCLS and the BSAC breakpoints, respectively, and 1.4% were resistant to quinupristin/dalfopristin irrespective of which breakpoint was used (Tables IV and V) . All enterococcal isolates were susceptible to linezolid and evernimicin using the tentative MIC breakpoint of 4 mg/L (Tables III and V) .
21,29
Discussion
Antibiotic resistance of isolates from ICUs has been shown to be at a lower level in Sweden compared with other European countries. 30 This study demonstrates that multidrug resistance is common among E. faecium isolates, and at levels similar to other European countries, although vancomycin resistance is still sporadic in Sweden.
10,31,32 Of the 322 isolates collected, 74 were E. faecium (23%), more than elsewhere in Europe, 31, 32 although these studies were not based on the ICU patient population.
Four isolates were vanC-carrying species other than E. faecalis or E. faecium. The significance of vanC-carrying enterococcal species has recently been reviewed. 33 Although serious infections may occur, many treatment options most often remain available, in contrast to enterococci with acquired resistance to vancomycin. On the basis of these conclusions we chose to exclude the four vanCcarrying isolates.
MICs in this study were performed by Etest according to the manufacturer's instructions and the SRGA's recommendations. 15 The recommended growth medium is PDM or IsoSensitest agar (Oxoid, Basingstoke, UK) by the SRGA 15 and Iso-Sensitest agar by the BSAC. 16 Etest MICs correlate well with the reference method (agar dilution) using these media. 15 Etest has been approved by the Food and Drug Administration using Mueller-Hinton agar, and correlates well with reference methods recommended by the NCCLS. 28, 34, 35 Ampicillin and fluoroquinolones Enterococci in general, and E. faecium in particular, are intrinsically relatively resistant to penicillin and ampicillin compared with other streptococci, with MICs of up to 8 mg/L for E. faecalis or higher for E. faecium. [36] [37] [38] In the late 1980s an increasing number of enterococcal isolates, mainly E. faecium, were reported to have even higher MICs (Ͼ100 mg/L), 4, 8 due to overproduction of a lowaffinity penicillin-binding protein (PBP) and a further decrease in the affinity of one of these PBPs. 8, 39 In our study, 55 isolates (74%) of E. faecium were resistant to ampicillin according to all breakpoints used, and 40 isolates (54%) showed MICs у 100 mg/L (Table V) . This is in agreement with studies performed mainly on hospitalized patients in the USA and Europe in the 1990s, although ICU wards were not specifically assessed. 5, 6 Forty-four (80%) of these 55 isolates with resistance to ampicillin in our study were concomitantly resistant to all fluoroquinolones tested. This is in agreement with the Swedish colonization study by Torell et al., 13 who showed that 91% of ampicillin-resistant enterococci were concomitantly resistant to ciprofloxacin. Trovafloxacin and clinafloxacin have both recently been restricted or withdrawn from clinical use because of toxicity. Although these new quinolones showed better activity (Table V) compared with ciprofloxacin, resistance was not uncommon and was, with two exceptions, only present in isolates resistant to ciprofloxacin (Tables III and IV) , suggesting cross resistance.
High-level aminoglycoside resistance
In a recent study in 27 European countries, HLGR was as frequent in E. faecium (23%) and E. faecalis (20%). 32 In contrast to these results, HLGR was not detected in any strain of E. faecium in our study. Twenty per cent of E. faecalis demonstrated HLGR, and all but one isolate with HLGR was resistant to all fluoroquinolones, in accordance with earlier studies. 40, 41 In the European study by Schouten et al., 32 resistance to ciprofloxacin and HLGR was found in enterococcal isolates from all 27 participant countries. Although clonal spread has been discussed, no explanation for this concomitant resistance has been confirmed. 32 
Vancomycin and teicoplanin
Only two isolates (both E. faecium) were resistant to vancomycin when applying the SRGA breakpoints, in Table V accordance with sporadic reports of vancomycin-resistant enterococci (VRE) in Swedish hospitals 12,13 and in contrast to findings from many other countries. 6, 10, 11 This might be the result of the restricted use of vancomycin or because outbreaks have been limited by infection control interventions. 15 It may also be influenced by the fact that use of antibiotics as growth promoters in animal food has been banned in Sweden since 1986. 42 The vancomycin-resistant E. faecium strains carried the vanB genotype, and although isolated from the same patient, had different antibiograms with MICs of ampicillin of 8 and 512 mg/L, respectively. When applying the NCCLS breakpoint, one of the isolates (VRE no. 2) was interpreted as intermediate. To distinguish enterococci with acquired resistance (VanA or VanB) from intrinsically resistant isolates (VanC), the NCCLS recommends biochemical tests (motility and pigmentation tests) when the vancomycin MIC is 8-16 mg/L in order to identify isolates of E. gallinarium and E. casseliflavus. 17 In our study the series of biochemical tests performed 23, 24 identified this isolate (VRE no. 2) as E. faecium, indicating an acquired resistance to vancomycin, and vanB was confirmed with multiplex PCR. However, biochemical tests are sometimes inconclusive in identifying enterococci to the species level, 26, 33 and identification of vancomycin resistance genes is of value in the identification of enterococci with MICs of vancomycin of 8-32 mg/L. 33 Quinupristin/dalfopristin E. faecalis is intrinsically resistant to quinupristin/dalfopristin; 43 however, it has been used successfully to treat infections due to E. faecium. 44, 45 Recent studies, however, have described the emergence of resistance during therapy. 46 In our study all E. faecalis were resistant using the NCCLS breakpoint, and only 1% were susceptible when applying the BSAC breakpoint. Of the E. faecium isolates, 78% or 98% were susceptible using the NCCLS or BSAC breakpoint, respectively, and one isolate was resistant (1.4%). These results are in accordance with most of the recent international and European studies where susceptibilities between 79 and Ͼ95% for E. faecium isolates have been reported, 18,47,48 although susceptibility as low as 45% was reported in one study. 49 
Linezolid
All enterococcal isolates were susceptible at the tentative MIC breakpoint of 4 mg/L (Table II) III and V), which is in agreement with earlier studies. 20 Evernimicin has recently been withdrawn from further development because of toxicity. 
Conclusions
